LGK974
Total Payments
$896,905
Transactions
37
Doctors
7
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $143,358 | 16 | 7 |
| 2019 | $631,294 | 7 | 0 |
| 2018 | $38,264 | 8 | 1 |
| 2017 | $83,989 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $896,905 | 37 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I OPEN LABEL DOSE ESCALATION STUDY OF ORAL LGK974 IN PATIENTS WITH MALIGNANCIES DEPENDENT ON WNT LIGANDS | Novartis Pharmaceuticals Corporation | $886,952 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $9,534 | 7 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $419.25 | 1 |
Top Doctors Receiving Payments for LGK974
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Detroit, MI | $886,952 | 27 |
| , MD | Medical Oncology | Houston, TX | $1,919 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | Boston, MA | $1,678 | 2 |
| , M.D, PHD | Internal Medicine | Houston, TX | $1,678 | 2 |
| , MD | Internal Medicine | Ann Arbor, MI | $1,500 | 1 |
| , MD | Medical Oncology | Ann Arbor, MI | $1,500 | 1 |
| , MB | Medical Oncology | Baltimore, MD | $1,500 | 1 |
| , MD | Hematology & Oncology | Detroit, MI | $178.00 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $896,486
- NOVARTIS PHARMACEUTICALS CORPORATION $419.25
Product Information
- Type Drug
- Total Payments $896,905
- Total Doctors 7
- Transactions 37
About LGK974
LGK974 is a drug associated with $896,905 in payments to 7 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $143,358 was paid across 16 transactions to 7 doctors.
The most common payment nature for LGK974 is "Unspecified" ($896,905, 100.0% of total).
LGK974 is associated with 3 research studies, including "A PHASE I OPEN LABEL DOSE ESCALATION STUDY OF ORAL LGK974 IN PATIENTS WITH MALIGNANCIES DEPENDENT ON WNT LIGANDS" ($886,952).